US filing the first worldwide for JT/GSK's MEK inhibitor for melanoma
This article was originally published in Scrip
Executive Summary
Japan Tobacco's trametinib has been filed for approval in the US by global licensee GlaxoSmithKline, for the treatment of unresectable or metastatic melanoma. The filing is the first to be made worldwide for the MEK inhibitor, JT in Japan told Scrip.
You may also be interested in...
Santen Gains Ready-Made US Portfolio Via $225m Eyevance Buy
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Atlas, Rise! Japan Cancer Center Builds Asia Trial Network
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.
Need a specific report? 1000+ reports available
Buy Reports